Motzer RJ, et al. - Researchers compared avelumab plus axitinib with the standard-of-care sunitinib in previously untreated patients with advanced renal-cell carcinoma. Patients were randomly assigned in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). They randomly assigned 886 patients to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). According to this phase 3 trial, progression-free survival among patients receiving these agents as first-line treatment for advanced renal cell carcinoma was significantly longer with avelumab plus axitinib than with sunitinib.